Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease: treatment of motor symptoms in PD. Mov Disord. 2018;33(8):1248–66.
Article CAS PubMed Google Scholar
Hauser RA. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756.
Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–71.
Article CAS PubMed Google Scholar
Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S2-41.
Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196–205.
Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009;8(10):929–37.
Article CAS PubMed Google Scholar
Guide parcours de soins maladie de Parkinson [Internet]. Haute Autorité de Santé. [accessed 1 sept 2023]. Available at: https://www.has-sante.fr/jcms/c_1242645/fr/guide-parcours-de-soins-maladie-de-parkinson
Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, et al. Descriptive analysis of the French NS-Park registry: towards a nation-wide Parkinson’s disease cohort? Parkinsonism Relat Disord. 2019;64:226–34.
Clarke CE, Patel S, Ives N, Rick CE, Woolley R, Wheatley K, et al. UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria [Internet]. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson’s disease: a large pragmatic randomised controlled trial (PD REHAB). NIHR Journals Library; 2016 [accessed 18 August 2021]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK379754/
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.
Article CAS PubMed Google Scholar
Allaire JJ, Ellis P, Gandrud C, Kuo K, Lewis BW, Owen J, et al. networkD3: D3 JavaScript Network Graphs from R [Internet]. 2017 [accessed 21 May 2024]. Available at: https://cran.r-project.org/web/packages/networkD3/index.html
Gabadinho A, Studer M, Müller N, Bürgin R, Fonta PA, Ritschard G. TraMineR: Trajectory Miner: a Sequence Analysis Toolkit [Internet]. 2024 [accessed 21 May 2024]. Available: https://cran.r-project.org/web/packages/TraMineR/index.html
Zhang Z, Sun J. Interval censoring. Stat Methods Med Res. 2010;19(1):53–70.
Anderson-Bergman C. icenReg: Regression Models for Interval Censored Data [Internet]. 2020 [accessed 6 oct 2022]. Available at: https://CRAN.R-project.org/package=icenReg
Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):e189-201.
Article CAS PubMed PubMed Central Google Scholar
De Micco R, Satolli S, Siciliano M, De Mase A, Giordano A, Tedeschi G, et al. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study. Neurol Sci janv. 2022;43(1):357–64.
Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepiness in patients with Parkinson’s disease before and after dopaminergic treatment. Euro J Neurology mars. 2005;12(3):199–207.
Ataide M, Franco CMR, Lins OG. Daytime sleepiness in Parkinson’s disease: perception, influence of drugs, and mood disorder. Sleep Disord. 2014;2014: 939713.
Article CAS PubMed PubMed Central Google Scholar
Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD. Development of excessive daytime sleepiness in early Parkinson disease. Neurology. 2015;85(2):162–8.
Feng F, Cai Y, Hou Y, Ou R, Jiang Z, Shang H. Excessive daytime sleepiness in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2021;85:133–40.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–91.
Article CAS PubMed Google Scholar
Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson’s disease: a case-control study. BMC Neurol. 2009;9:23.
Article PubMed PubMed Central Google Scholar
Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008;2:6564.
Mai AS, Lee YS, Yong JH, Teo DCYJ, Wan YM, Tan EK. Treatment of apathy in Parkinson’s disease: a Bayesian network meta-analysis of randomised controlled trials. Heliyon. 2024;10(4): e26107.
Article PubMed PubMed Central Google Scholar
Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms—results of a double-blind, randomized, placebo-controlled trial. Euro J Neurol. 2015;22(10):1400–7.
Tsuboi T, Satake Y, Hiraga K, Yokoi K, Hattori M, Suzuki M, et al. Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: a systematic review. NPJ Parkinsons Dis. 2022;8(1):1–21.
Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004;329(7466):593.
Article CAS PubMed PubMed Central Google Scholar
Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(10):2731–42.
Article PubMed PubMed Central Google Scholar
Orayj K, Lane E. Patterns and determinants of prescribing for Parkinson’s disease: a systematic literature review. Parkinsons Dis. 2019;2019:9237181.
PubMed PubMed Central Google Scholar
Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, et al. Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. Neurology. 2021;97(20):942–57.
Article PubMed PubMed Central Google Scholar
Debove I, Paschen S, Amstutz D, Cardoso F, Corvol JC, Fung VSC, et al. Management of impulse control and related disorders in Parkinson’s disease: an expert consensus. Mov Disord. 2024;39(2):235–48.
Faouzi J, Bekadar S, Artaud F, Elbaz A, Mangone G, Colliot O, et al. Machine learning-based prediction of impulse control disorders in Parkinson’s disease from clinical and genetic data. IEEE Open J Eng Med Biol. 2022;3:96–107.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.
Comments (0)